Cynata Therapeutics Limited (CYYNF)
USD 0.3
(117.39%)
USD 0.3
(117.39%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -12.54 Million AUD | 24.16% |
| 2023 | -16.54 Million AUD | -19.54% |
| 2022 | -13.83 Million AUD | -52.39% |
| 2021 | -9.08 Million AUD | 13.62% |
| 2020 | -10.51 Million AUD | -4.49% |
| 2019 | -10.06 Million AUD | -64.1% |
| 2018 | -6.13 Million AUD | 3.18% |
| 2017 | -6.33 Million AUD | -2.44% |
| 2016 | -6.18 Million AUD | -45.07% |
| 2015 | -4.26 Million AUD | -35.38% |
| 2014 | -3.14 Million AUD | -244.09% |
| 2013 | -914.72 Thousand AUD | 40.62% |
| 2012 | -1.54 Million AUD | 39.74% |
| 2011 | -2.55 Million AUD | -21.4% |
| 2010 | -2.1 Million AUD | -47.13% |
| 2009 | -1.43 Million AUD | 3.49% |
| 2008 | -1.48 Million AUD | 0.0% |
| 2007 | - AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q4 | -5.39 Million AUD | 0.0% |
| 2024 Q1 | -2.27 Million AUD | 75.61% |
| 2024 Q2 | -7.08 Million AUD | -212.12% |
| 2024 FY | -12.54 Million AUD | 24.16% |
| 2023 FY | -16.54 Million AUD | -19.54% |
| 2023 Q1 | -2.58 Million AUD | 50.05% |
| 2023 Q3 | -4.85 Million AUD | 30.35% |
| 2023 Q4 | -9.31 Million AUD | -91.67% |
| 2023 Q2 | -6.97 Million AUD | -169.63% |
| 2022 Q3 | -2.46 Million AUD | -111.99% |
| 2022 Q2 | -1.16 Million AUD | -105.86% |
| 2022 FY | -13.83 Million AUD | -52.39% |
| 2022 Q1 | -565.59 Thousand AUD | 87.2% |
| 2022 Q4 | -5.17 Million AUD | -109.8% |
| 2021 Q2 | -4.95 Million AUD | -101.12% |
| 2021 Q1 | -2.46 Million AUD | 33.71% |
| 2021 FY | -9.08 Million AUD | 13.62% |
| 2021 Q3 | -1.3 Million AUD | 73.74% |
| 2021 Q4 | -4.42 Million AUD | -239.49% |
| 2020 Q4 | -3.71 Million AUD | -748.8% |
| 2020 Q1 | -1.31 Million AUD | 76.66% |
| 2020 FY | -10.51 Million AUD | -4.49% |
| 2020 Q2 | -7.07 Million AUD | -439.06% |
| 2020 Q3 | -438.11 Thousand AUD | 93.81% |
| 2019 Q1 | -1.55 Million AUD | -5.77% |
| 2019 Q2 | -1.55 Million AUD | 0.0% |
| 2019 FY | -10.06 Million AUD | -64.1% |
| 2019 Q4 | -5.62 Million AUD | -99.29% |
| 2019 Q3 | -2.82 Million AUD | -81.45% |
| 2018 Q4 | -1.47 Million AUD | 0.0% |
| 2018 Q2 | -907.85 Thousand AUD | 0.0% |
| 2018 Q1 | -907.85 Thousand AUD | 49.03% |
| 2018 FY | -6.13 Million AUD | 3.18% |
| 2018 Q3 | -1.47 Million AUD | -61.93% |
| 2017 Q4 | -1.78 Million AUD | 0.0% |
| 2017 FY | -6.33 Million AUD | -2.44% |
| 2017 Q1 | -510.68 Thousand AUD | 60.92% |
| 2017 Q3 | -1.78 Million AUD | -248.78% |
| 2017 Q2 | -510.68 Thousand AUD | 0.0% |
| 2016 FY | -6.18 Million AUD | -45.07% |
| 2016 Q2 | -1.23 Million AUD | 0.0% |
| 2016 Q1 | -1.23 Million AUD | 3.46% |
| 2016 Q4 | -1.3 Million AUD | 0.0% |
| 2016 Q3 | -1.3 Million AUD | -5.89% |
| 2015 Q3 | -1.27 Million AUD | -80.21% |
| 2015 Q4 | -1.27 Million AUD | 0.0% |
| 2015 Q2 | -709.36 Thousand AUD | 0.0% |
| 2015 Q1 | -709.36 Thousand AUD | -3.54% |
| 2015 FY | -4.26 Million AUD | -35.38% |
| 2014 Q4 | -685.08 Thousand AUD | 0.0% |
| 2014 Q3 | -685.08 Thousand AUD | 21.8% |
| 2014 Q2 | -876.09 Thousand AUD | 0.0% |
| 2014 Q1 | -876.09 Thousand AUD | -290.93% |
| 2014 FY | -3.14 Million AUD | -244.09% |
| 2013 Q4 | -224.1 Thousand AUD | 0.0% |
| 2013 FY | -914.72 Thousand AUD | 40.62% |
| 2013 Q3 | -224.1 Thousand AUD | 0.0% |
| 2012 FY | -1.54 Million AUD | 39.74% |
| 2011 FY | -2.55 Million AUD | -21.4% |
| 2010 FY | -2.1 Million AUD | -47.13% |
| 2009 FY | -1.43 Million AUD | 3.49% |
| 2008 FY | -1.48 Million AUD | 0.0% |
| 2007 FY | - AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Qrons Inc. | -643.67 Thousand USD | -1849.085% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 115.327% |
| Nascent Biotech, Inc. | -2.22 Million USD | -462.623% |
| Adynxx, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 20.945% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -898.87% |
| BioStem Technologies, Inc. | -7.77 Million USD | -61.279% |
| CSL Limited | 3.7 Billion USD | 100.339% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -148.704% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 29.704% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 77.398% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1726.306% |
| Skye Bioscience, Inc. | -13.67 Million USD | 8.236% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -2919.601% |
| Rebus Holdings, Inc. | -664 Thousand USD | -1789.429% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -839.458% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -3120.425% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 82.523% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 355.265% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -4693.49% |
| SQZ Biotechnologies Company | -75.82 Million USD | 83.454% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -340.126% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -716.758% |
| Mesoblast Limited | -84.14 Million USD | 85.091% |
| Marizyme, Inc. | -34.08 Million USD | 63.194% |
| Genus plc | 6.4 Million USD | 296.028% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 228.775% |
| Pharming Group N.V. | -4.87 Million USD | -157.11% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -531.56% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -1247.013% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -50.249% |
| ContraFect Corporation | -56.88 Million USD | 77.947% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -175.446% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -794.857% |
| IMV Inc. | -38.67 Million USD | 67.558% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -356.072% |
| MultiCell Technologies, Inc. | -722.81 USD | -1735599.561% |
| ONE Bio Corp. | 13.68 Million USD | 191.699% |
| Accustem Sciences Inc. | -3.74 Million USD | -234.875% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 78.732% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -2497.143% |
| Q BioMed Inc. | -3.44 Million USD | -264.109% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 454.401% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -377.477% |
| Biomind Labs Inc. | -1 Million USD | -1142.648% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 77.178% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -332.428% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -88.715% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -572.925% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -41786.385% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -549.164% |
| GB Sciences, Inc. | -1.42 Million USD | -783.191% |
| Alpha Cognition Inc. | -9.7 Million USD | -29.264% |
| HST Global, Inc. | -140.9 Thousand USD | -8803.61% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -1015.276% |
| Halberd Corporation | -75.05 Thousand USD | -16616.602% |
| Enzolytics Inc. | -2.14 Million USD | -483.852% |
| Agentix Corp. | -1.37 Million USD | -814.58% |
| Resverlogix Corp. | -12.74 Million USD | 1.594% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -295.982% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 97.048% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -1101.706% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -329.733% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -694.363% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -268.455% |
| AVAX Technologies, Inc. | 6.69 Million USD | 287.45% |
| Zenith Capital Corp. | -8.94 Million USD | -40.286% |
| Genscript Biotech Corporation | -415.79 Million USD | 96.983% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -71915.441% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -410.965% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -7214.934% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -525.802% |
| Kadimastem Ltd | -3.04 Million USD | -312.657% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -1174.912% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -6812.863% |
| LadRx Corporation | -3.82 Million USD | -228.113% |
| Cell Source, Inc. | -4.32 Million USD | -190.053% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1726.306% |
| NovAccess Global Inc. | -2.46 Million USD | -408.595% |
| Affymax, Inc. | -15.04 Million USD | 16.617% |
| Itoco Inc. | -919.14 Thousand USD | -1264.951% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -196.002% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1021.163% |
| Mobile Lads Corp. | -554.55 Thousand USD | -2162.341% |
| CytoDyn Inc. | -18.05 Million USD | 30.525% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -49744.299% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -5600.62% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -2121.587% |
| SYBLEU INC | -149.18 Thousand USD | -8309.847% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -590.727% |
| International Stem Cell Corporation | -663 Thousand USD | -1792.279% |
| Bioxytran, Inc. | -3.82 Million USD | -228.412% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -23733.226% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -61580.482% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 65.406% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -675.39% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -1604.976% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -303.273% |
| Neutra Corp. | -229.48 Thousand USD | -5366.917% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 28.469% |
| PureTech Health plc | -146.19 Million USD | 91.419% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 41.623% |
| IXICO plc | -1.43 Million USD | -773.056% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -32.186% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 89.7% |
| CSL Limited | 3.81 Billion USD | 100.329% |
| Cellectis S.A. | -108.85 Million USD | 88.475% |